Cargando…
COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449708/ http://dx.doi.org/10.1016/j.nmd.2021.07.049 |
| _version_ | 1784569474474573824 |
|---|---|
| author | James, M. Alfano, L. Rose, K. Lowes, L. Eagle, M. |
| author_facet | James, M. Alfano, L. Rose, K. Lowes, L. Eagle, M. |
| author_sort | James, M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8449708 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84497082021-09-20 COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies James, M. Alfano, L. Rose, K. Lowes, L. Eagle, M. Neuromuscul Disord Article Published by Elsevier B.V. 2021-10 2021-09-18 /pmc/articles/PMC8449708/ http://dx.doi.org/10.1016/j.nmd.2021.07.049 Text en Copyright © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article James, M. Alfano, L. Rose, K. Lowes, L. Eagle, M. COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title | COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title_full | COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title_fullStr | COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title_full_unstemmed | COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title_short | COVID-19 AND NEUROMUSCULAR DISEASES: EP.24 COVID-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| title_sort | covid-19 and neuromuscular diseases: ep.24 covid-19 mitigation strategies for outcome measure assessments, training, and endpoint collection in clinic, clinical trials and natural history studies |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449708/ http://dx.doi.org/10.1016/j.nmd.2021.07.049 |
| work_keys_str_mv | AT jamesm covid19andneuromusculardiseasesep24covid19mitigationstrategiesforoutcomemeasureassessmentstrainingandendpointcollectioninclinicclinicaltrialsandnaturalhistorystudies AT alfanol covid19andneuromusculardiseasesep24covid19mitigationstrategiesforoutcomemeasureassessmentstrainingandendpointcollectioninclinicclinicaltrialsandnaturalhistorystudies AT rosek covid19andneuromusculardiseasesep24covid19mitigationstrategiesforoutcomemeasureassessmentstrainingandendpointcollectioninclinicclinicaltrialsandnaturalhistorystudies AT lowesl covid19andneuromusculardiseasesep24covid19mitigationstrategiesforoutcomemeasureassessmentstrainingandendpointcollectioninclinicclinicaltrialsandnaturalhistorystudies AT eaglem covid19andneuromusculardiseasesep24covid19mitigationstrategiesforoutcomemeasureassessmentstrainingandendpointcollectioninclinicclinicaltrialsandnaturalhistorystudies |